Stock listing

NASDAQ:TELO Telomir Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Telomir Pharmaceuticals, Inc.

Follow Telomir Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TELO

$0.364 USD -0.056 (-13.4%)

Close on Nov 20, 2026

Past year -73.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.358 – $0.437 USDNov 20, 2026
Volume
255,911 sharesNov 20, 2026
Market cap
$26.82M USDAt the close on Nov 20, 2026 · price × 73.68M shares outstanding
52-week range
$0.358 – $1.580 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$111,939 USDMedian day 64,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Telomir Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TELO · Home$0.364 USD-0.056 (-13.4%)255,911$0.430$0.437$0.358$0.421Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TELO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.364-0.056-13.4%$0.430$0.437$0.358255,911
$0.421-0.003-0.6%$0.448$0.448$0.420151,191
$0.423-0.058-12.0%$0.468$0.500$0.401326,017
$0.481-0.010-2.0%$0.474$0.517$0.446481,515
$0.491-0.010-2.0%$0.492$0.572$0.488124,262
$0.500-0.095-15.9%$0.595$0.630$0.470228,612
$0.595+0.023+4.0%$0.587$0.710$0.573321,147
$0.572-0.118-17.1%$0.690$0.699$0.545431,670
$0.690-0.020-2.8%$0.710$0.730$0.670170,630
$0.710-0.070-9.0%$0.775$0.820$0.693152,252
$0.780-0.095-10.8%$0.832$0.870$0.780166,377
$0.875-0.035-3.8%$0.910$0.930$0.855235,434
$0.910-0.005-0.6%$0.940$0.950$0.91054,234
$0.915-0.020-2.1%$0.940$0.960$0.90758,043
$0.935-0.029-3.0%$0.960$0.990$0.79196,698
$0.964-0.046-4.5%$0.980$1.010$0.962115,058
$1.010-0.010-1.0%$1.000$1.050$0.98044,535
$1.020+0.021+2.2%$1.030$1.070$1.01053,982
$0.999+0.024+2.4%$1.000$1.045$0.97541,887
$0.975-0.035-3.5%$0.980$0.990$0.96048,800
$1.010-0.010-1.0%$1.030$1.030$0.97093,400
$1.020+0.010+1.0%$1.010$1.060$1.01037,700
$1.010-0.030-2.9%$1.020$1.050$1.00078,000
$1.040-0.010-1.0%$1.050$1.099$1.03029,200
$1.0500.0000.0%$1.040$1.130$1.04039,200
$1.0500.0000.0%$1.040$1.070$1.01069,300
$1.050-0.040-3.7%$1.100$1.105$1.03086,900
$1.090-0.010-0.9%$1.100$1.200$1.07553,800
$1.100-0.020-1.8%$1.130$1.140$1.09070,900
$1.120-0.030-2.6%$1.160$1.160$1.10064,600
$1.150+0.030+2.7%$1.110$1.150$1.100131,500
$1.120-0.080-6.7%$1.160$1.170$1.120124,500
$1.200-0.010-0.8%$1.250$1.580$1.1701,253,700
$1.210+0.030+2.5%$1.240$1.270$1.190134,400
$1.180+0.010+0.9%$1.170$1.220$1.17074,100
$1.170-0.030-2.5%$1.200$1.220$1.15059,700
$1.200+0.030+2.6%$1.190$1.240$1.17043,300
$1.170-0.030-2.5%$1.190$1.200$1.16034,300
$1.200-0.030-2.4%$1.235$1.235$1.17072,100
$1.230+0.020+1.7%$1.220$1.230$1.20056,000
$1.210-0.010-0.8%$1.210$1.240$1.21031,100
$1.220-0.030-2.4%$1.240$1.245$1.21034,600
$1.250+0.010+0.8%$1.250$1.290$1.210103,200
$1.240+0.010+0.8%$1.230$1.245$1.19046,400
$1.230+0.110+9.8%$1.150$1.300$1.130480,500
$1.120-0.010-0.9%$1.180$1.240$1.100146,400
$1.130-0.040-3.4%$1.144$1.169$1.13037,700
$1.1700.0000.0%$1.160$1.179$1.14027,200
$1.1700.0000.0%$1.120$1.198$1.11550,000
$1.170-0.010-0.8%$1.180$1.208$1.11033,100
$1.180-0.040-3.3%$1.190$1.220$1.17532,500
$1.220+0.030+2.5%$1.190$1.230$1.18032,100
$1.190+0.030+2.6%$1.140$1.230$1.13074,900
$1.1600.0000.0%$1.170$1.190$1.16033,900
$1.160+0.040+3.6%$1.120$1.170$1.11064,200
$1.120+0.020+1.8%$1.110$1.130$1.08931,400
$1.100-0.020-1.8%$1.130$1.130$1.08519,600
$1.120-0.020-1.8%$1.110$1.140$1.08045,400
$1.140-0.050-4.2%$1.200$1.200$1.14038,200
$1.190+0.020+1.7%$1.160$1.200$1.145130,200
$1.170-0.010-0.8%$1.170$1.200$1.14169,000
$1.180+0.010+0.9%$1.180$1.196$1.15640,500
$1.170+0.040+3.5%$1.130$1.200$1.13056,400
$1.1300.0000.0%$1.130$1.160$1.11043,300
$1.130-0.040-3.4%$1.180$1.180$1.11035,300
Ticker
NASDAQ:TELO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Telomir Pharmaceuticals, Inc. news

Telomir Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 58 in all · newest Nov 18, 2026 · oldest 2024
Decks
9 decks · latest July 2026

Where Telomir Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TELO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TELOBOATSUnited StatesUSD

Valuation

Price/book 6.1× against a median of 1.9×: 9th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$22.30M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
6.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.74

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Telomir Pharmaceuticals, Inc. · NASDAQ:TELOUS$26.82MUS$22.30Mn/an/an/a6.1×n/a0.0×1.74
Holy Stone Healthcare Co., Ltd. · TPEX:4194US$27.49MUS$25.08Mn/an/an/a7.3×n/a0.0×n/a
SoftOx Solutions AS · OSL:SOFTXUS$27.28MUS$25.25Mn/an/an/a11.6×n/a0.0×n/a
Edesa Biotech, Inc. · NASDAQ:EDSAUS$27.02MUS$16.72Mn/an/an/a3.1×n/a0.0×0.47
Amplia Therapeutics Ltd. · ASX:ATXUS$26.84MUS$8.63Mn/an/an/a1.0×n/a0.0×n/a
Nasus Pharma Ltd. · AMEX:NSRXUS$26.82MUS$15.11Mn/an/an/a2.4×n/a0.0×0.99
BriaCell Therapeutics Corp · TSX:BCTUS$26.79MUS$6.25Mn/an/an/a1.7×n/a0.0×1.07
Alterity Therapeutics Ltd. · ASX:ATHUS$26.76MUS$2.18Mn/an/an/a0.9×n/a0.0×n/a
EyePoint, Inc. · NASDAQ:EYPTUS$26.65M−US$72.44Mn/a−28.1×n/a0.3×n/a0.2×1.36
Aprogen, Inc · KRX:007460US$26.64MUS$21.31Mn/a0.2×n/a0.6×−60.1%0.6×n/a
PolTREG Spolka Akcyjna · GPW:PTGUS$26.09MUS$22.35Mn/a378×n/a2.2×n/a0.1×n/a
Median of the othersUS$26.81MUS$15.92M0.2×1.9×−60.1%0.0×1.03

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.11 · 1 analyst

Team and board

Officers

OfficerRole
Erez AminovChairman and Chief Executive Officer
Andriy MushakChief Financial Officer

Board

DirectorRole
Erez AminovChairman and Chief Executive Officer
Matthew P. Del GiudiceDirector
Matthew Pratt WhalenDirector
Ned MacPhersonDirector

Events

QuarterResultsShare move
Q3 2026Nov 6, 2026 · After close−2.8%
Q2 2026Aug 13, 2026−1.8%
Q1 2026May 12, 2026 · After close−2.4%
Q4 2025Feb 25, 2026+8.3%
Q3 2025Nov 10, 2025 · After close+3.6%
Q2 2025Aug 14, 2025 · After close−5.1%
Q1 2025May 14, 2025 · After close−11.3%
Q4 2024Feb 4, 2025 · After close+3.2%
Q3 2024Nov 11, 2024 · After close−4.3%
Q2 2024Aug 13, 2024 · After close−15.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck25 slidesJuly 2026
Investor Presentation (April 2026)Investor deck43 slidesApril 2026
Investor Presentation (February 2026)Investor deck70 slidesFebruary 2026
Investor Presentation (November 2025)Investor deck63 slidesNovember 2025
Bio Presentation (June 2025)Conference30 slidesJune 2025
Investor Presentation (February 2025)Investor deck28 slidesFebruary 2025
Investor Presentation (January 2025)Investor deck28 slidesJanuary 2025
Investor Presentation (August 2024)Investor deck27 slidesAugust 2024
Corporate Update (April 2024)Corporate update31 slidesApr 15, 2024

Open Decks

Financings

RaiseDate
Private placement of common stock
Announced: about US$5.6M · US$1.16 a share · Alexander Capital, L.P.
Dealers: Alexander Capital, L.P. (lead)
Buyers: John Paul DeJoria (additional $1.0 million investment)
Use of proceeds: Clinical development of Telomir-Zn, including its Phase 1/2 program in advanced or metastatic TNBC, plus working capital and general corporate purposes
Oct 6, 2026
Capital contributions from former TELI shareholders
Closed: US$1M raised
Buyers: Certain former TELI shareholders ($1.0 million funded at closing; up to an additional $4.0 million in milestone-based contributions)
Apr 27, 2026
Milestone shares of common stock
Announced: up to US$5M
Buyers: certain TELI shareholders (up to $5 million in cash or cash equivalents: $1 million at closing, $2 million upon IND acceptance, $2 million upon Phase 1/2 initiation)
Use of proceeds: To advance development of Telomir-1
Oct 21, 2025
Strategic investment of restricted shares of common stock
Closed: US$3M raised · US$3 a share
Buyers: The Bayshore Trust (1 million restricted shares at $3.00 per share for $3 million)
Insiders: Purchased entirely by The Bayshore Trust, the Company's largest shareholder
Use of proceeds: Fund Telomir-1's upcoming IND submission for a rare disease indication and strengthen the balance sheet
May 21, 2025
Strategic investment of common stock
Closed: US$1M in the latest tranche · US$7 a share
Buyers: The Starwood Trust ($1 million in common stock at $7 per share)
Use of proceeds: To advance its scientific research and product development activities
Dec 17, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$7.00 a share on Feb 8, 2024.

Price
US$7.00 a share
Shares offered
1,000,000 shares of common stock
Offering size
US$7 million
Underwriters' option
Up to 150,000 more shares
Listing
TELO on the Nasdaq Capital Market
Underwriter
Kingswood Investments
Shares delivered
On or about Feb 13, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceAug 14, 2023
Filed publiclyNov 14, 2023
Amended 3 timesNewest Jan 3, 2024
Shares registered with an exchangeFeb 6, 2024
Declared effective by the SECFeb 8, 2024
Final prospectus, with the priceFeb 12, 2024

Open IPO · From the cover of the final prospectus (424B1) filed Feb 12, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2022FY2021
Revenue00000
Cost of revenue3.94M
Gross profit-3.94M
Research and development2.44M2.44M2.24M2.24M1.57M1.57M833.2K833.2K126.5K
Selling, general and administrative8.10M9.64M600.2K20.9K11.6K
Operating income-10.5M-12.2M-3.94M-854.1K-138.1K
Depreciation and amortization4.34M1.61M854.1K138.1K
EBITDA-7.90M-2.33M00
Interest expense04.34M4.34M1.64M1.64M0
Income before tax-10.4M-16.5M-13.1M-854.1K-138.1K
Income tax-16.5M-2.30M-854.1K-138.1K
Net income-10.4M-10.4M-16.5M-16.5M-13.1M-13.1M-854.1K-854.1K-138.1K
Earnings per share, basic-0.33-0.33-0.56-0.560.48-0.44-0.03-0.03-0.00
Earnings per share, diluted-0.33-0.560.48-0.03

Balance sheet

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2022FY2021
Cash and equivalents7.29M7.29M1.27M1.27M1.23K1.23K1.42K1.42K0
Receivables130.0K
Inventory303.3K
Current assets7.34M7.34M1.32M1.32M435.2K435.2K48.7K1.42K0
Total assets7.34M7.34M1.32M1.32M4.77M4.77M48.7K48.7K55.0K
Accounts payable536.8K587.5K707.2K404.2K18.7K
Current liabilities1.43M1.43M681.0K681.0K1.34M1.34M986.0K986.0K138.1K
Total debt473.8K93.4K101.0K581.8K119.4K
Total liabilities1.43M1.43M681.0K681.0K1.34M1.34M986.0K986.0K138.1K
Shareholders' equity5.91M5.91M643.0K643.0K3.44M3.44M-937.3K-937.3K-83.1K
Shares outstanding34.4M31.7M29.8M29.5M28.6M29.6M26.8M29.6M29.6M

Cash flow

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2022FY2021
Cash from operations-3.69M-3.69M-5.07M-5.07M-3.86M-3.86M-468.7K-468.7K-119.4K
Capital spending00-40-4
Free cash flow-3.69M-5.07M-3.86M-468.7K-119.4K
Cash from financing9.71M9.71M6.34M6.34M3.86M3.86M470.1K470.1K119.4K
Change in cash6.02M6.02M1.26M1.26M-188-1881.42K1.42K0

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 18, 2026Current reportSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveNov 6, 2026Other filingsSEC
424B3 · ProspectusNov 5, 2026Offer documentSEC
S-3 · Registration statementOct 27, 2026Offer documentSEC
8-K · Current reportOct 6, 2026Material contractSEC
8-K · Current reportSep 17, 2026Current reportSEC
8-K · Current reportSep 16, 2026Meeting outcomeSEC
8-K · Current reportSep 14, 2026Current reportSEC
DEFA14A · Additional proxy materialAug 19, 2026Meeting noticeSEC
All 151 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026Current reportSEC
DEF 14A · Proxy statementJul 28, 2026Meeting noticeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
8-K · Current reportJun 15, 2026Current reportSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Management or board changeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
8-K · Current reportMay 20, 2026Current reportSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportApr 30, 2026Current reportSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
8-K · Current reportApr 24, 2026Acquisition or disposalSEC
8-K · Current reportMar 31, 2026Current reportSEC
8-K · Current reportMar 31, 2026Current reportSEC
8-K · Current reportMar 27, 2026Management or board changeSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
DEFM14AFeb 19, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialFeb 19, 2026Meeting noticeSEC
8-K · Current reportFeb 17, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
8-K · Current reportFeb 5, 2026Current reportSEC
PRER14AFeb 4, 2026Other filingsSEC
PRER14AJan 23, 2026Other filingsSEC
8-K · Current reportJan 9, 2026Current reportSEC
8-K · Current reportJan 5, 2026Current reportSEC
8-K · Current reportDec 19, 2025Management or board changeSEC
8-K · Current reportDec 17, 2025Current reportSEC
PRER14ANov 28, 2025Other filingsSEC
8-K · Current reportNov 24, 2025Current reportSEC
8-K · Current reportNov 20, 2025Management or board changeSEC
PREM14ANov 20, 2025Other filingsSEC
8-K · Current reportNov 20, 2025Current reportSEC
8-K · Current reportNov 12, 2025Current reportSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportOct 22, 2025Current reportSEC
8-K · Current reportOct 20, 2025Material contractSEC
8-K · Current reportOct 14, 2025Current reportSEC
8-K · Current reportOct 8, 2025Current reportSEC
8-K · Current reportOct 6, 2025Current reportSEC
3 · Initial statement of ownershipOct 3, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeSep 18, 2025Big-stake noticeSEC
8-K · Current reportSep 18, 2025Current reportSEC
8-K · Current reportSep 9, 2025Current reportSEC
8-K · Current reportSep 4, 2025Current reportSEC
8-K · Current reportAug 27, 2025Current reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025Current reportSEC
8-K · Current reportJul 23, 2025Current reportSEC
8-K · Current reportJul 22, 2025Current reportSEC
8-K · Current reportJul 17, 2025Current reportSEC
8-K · Current reportJun 18, 2025Current reportSEC
8-K · Current reportJun 11, 2025Current reportSEC
3 · Initial statement of ownershipJun 10, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Current reportSEC
8-K · Current reportJun 2, 2025Current reportSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
8-K · Current reportMay 29, 2025Current reportSEC
8-K · Current reportMay 21, 2025Material contractSEC
8-K · Current reportMay 21, 2025FinancingSEC
8-K · Current reportMay 15, 2025Current reportSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025Current reportSEC
8-K · Current reportMar 19, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMar 3, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 26, 2025Other filingsSEC
8-K · Current reportFeb 25, 2025Current reportSEC
8-K · Current reportFeb 20, 2025Current reportSEC
UPLOAD · Letter from the SECFeb 20, 2025Other filingsSEC
8-K · Current reportFeb 18, 2025Current reportSEC
S-3 · Registration statementFeb 14, 2025Offer documentSEC
10-K · Annual reportFeb 4, 2025Annual reportSEC
5 · Annual statement of ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportJan 28, 2025Current reportSEC
8-K · Current reportJan 7, 2025Current reportSEC
8-K · Current reportDec 23, 2024Current reportSEC
8-K · Current reportDec 20, 2024Current reportSEC
8-K · Current reportDec 11, 2024FinancingSEC
8-K · Current reportDec 2, 2024Current reportSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
8-K · Current reportNov 21, 2024Management or board changeSEC
8-K · Current reportNov 20, 2024Current reportSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportSep 27, 2024Material contractSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
8-K · Current reportSep 3, 2024Current reportSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 29, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 15, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 15, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 15, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 15, 2024Insider tradeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportJun 21, 2024Management or board changeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportApr 15, 2024Current reportSEC
8-K · Current reportApr 12, 2024Management or board changeSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
8-K · Current reportFeb 13, 2024Material contractSEC
424B4 · ProspectusFeb 12, 2024Offer documentSEC
424B1 · ProspectusFeb 12, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 9, 2024Other filingsSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
CERT · Exchange's certificate of listingFeb 8, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 6, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 6, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 6, 2024Other filingsSEC
CORRESP · Letter to the SECJan 3, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 3, 2024Offer documentSEC
UPLOAD · Letter from the SECDec 19, 2023Other filingsSEC
S-1/A · Registration statement, amendedDec 19, 2023Offer documentSEC
CORRESP · Letter to the SECDec 14, 2023Other filingsSEC
S-1/A · Registration statement, amendedDec 14, 2023Offer documentSEC
UPLOAD · Letter from the SECNov 28, 2023Other filingsSEC
CORRESP · Letter to the SECNov 13, 2023Other filingsSEC
S-1 · Registration statementNov 13, 2023Offer documentSEC
UPLOAD · Letter from the SECNov 1, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftOct 16, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedOct 16, 2023Offer documentSEC
UPLOAD · Letter from the SECSep 18, 2023Other filingsSEC
DRS · Draft registration statementAug 14, 2023Offer documentSEC
DApr 3, 2023Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Telomir Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026

Common shares
73,675,706
Fully diluted
73,675,706

Fully diluted

LineSharesAs of
Common shares73,675,706Nov 5, 2026

Share count over time

CountShares
Nov 5, 202673,675,706

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard1.9M2.6%US$2.28MSep 30, 2026
Geode Capital438K0.59%US$526KSep 30, 2026
BlackRock364K0.49%US$437KSep 30, 2026
Citadel146K0.20%US$176KSep 30, 2026
Northern Trust105K0.14%US$126KSep 30, 2026
State Street58,6000.08%US$70,320Sep 30, 2026
BNY51,4540.07%US$61,744Sep 30, 2026
Captrust Financial Advisors51,1940.07%US$61,433Sep 30, 2026
Osaic Holdings, Inc.30,9900.04%US$36,962Sep 30, 2026
Praetorian Wealth Management, Inc.20,0000.03%US$24,000Sep 30, 2026
All 24 holders
HolderSharesOf the companyValueAs of
OneDigital Investment Advisors LLC14,5000.02%US$17,400Sep 30, 2026
Morton Capital Management LLC12,6580.02%US$15,190Sep 30, 2026
Clearstead Advisors, LLC12,5300.02%US$15,036Sep 30, 2026
Regions Financial Corp10,6380.01%US$12,766Sep 30, 2026
UBS7,170<0.01%US$8,604Sep 30, 2026
Nuveen2,996<0.01%US$3,745Sep 30, 2026
Tower Research Capital LLC (TRC)2,316<0.01%US$2,779Sep 30, 2026
RBC1,341<0.01%US$2,000Sep 30, 2026
Fidelity710<0.01%US$852Sep 30, 2026
Jones Financial Companies Lllp600<0.01%US$738Sep 30, 2026
BNP Paribas201<0.01%US$241Sep 30, 2026
JPMorgan121<0.01%US$142Sep 30, 2026
GK Wealth Management LLC100<0.01%US$120Sep 30, 2026
SBI Securities Co., Ltd.4<0.01%US$5Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.12M1.5%US$1.44MJun 30, 2026
Vanguard Extended Market Index Fund473K0.64%US$605KJun 30, 2026
Fidelity Extended Market Index Fund121K0.16%US$158KMay 31, 2026
iShares Micro-Cap ETF37,1720.05%US$47,580Jun 30, 2026
Fidelity Total Market Index Fund30,0990.04%US$39,129May 31, 2026
Fidelity Series Total Market Index Fund28,5200.04%US$37,076May 31, 2026
Vanguard Balanced Index Fund19,8410.03%US$25,396Jun 30, 2026
Fidelity Nasdaq Composite Index Fund18,4640.03%US$24,003May 31, 2026
1290 VT Micro Cap Portfolio2,473<0.01%US$3,165Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity5.17%3.55MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Christopher C Chapman Jr
Other companies: MIRA Pharmaceuticals, Inc. (Executive Chairman, Director · Aug 2, 2023 – Aug 17, 2023 · Past); Q/C Technologies, Inc. (President, Chief Med. Officer, Director · Apr 16, 2021 – Jun 7, 2023 · Past); Rock Creek Pharmaceuticals Inc (President, Director · Sep 22, 2006 – Dec 27, 2013 · Past)
CEO & Chairman, Director · Feb 8, 2024 – Feb 8, 2024 · Past
Craig Eagle
Other companies: OS Therapies Incorporated (Director · Since at least Jul 1, 2026); Guardant Health, Inc. (Chief Medical Officer · Since at least May 4, 2021); Q/C Technologies, Inc. (Director · Apr 16, 2021 – Jun 7, 2023 · Past)
Director · Feb 8, 2024 – Feb 8, 2024 · Past
Michael Jerman
Other companies: Alaunos Therapeutics, Inc. (Managing Partner of Hollywell Partners · Since at least Jul 15, 2025); Inhibitor Therapeutics Inc. (Director · Since at least Apr 1, 2024); MIRA Pharmaceuticals, Inc. (Director · Nov 14, 2023 – Mar 25, 2024 · Past)
Director · Feb 8, 2024 – Aug 27, 2024 · Past
Alan Weichselbaum
Other companies: FinWise Bancorp (Director · Since at least Oct 6, 2022); MIRA Pharmaceuticals, Inc. (Chief Financial Officer · May 15, 2025 – May 15, 2025 · Past)
Chief Financial Officer · May 15, 2025 – May 15, 2025 · Past
Hugh McColl III
Other companies: Westrock Coffee Company (Director · Since at least Aug 26, 2022); MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 2, 2023 · Past)
Director · Feb 8, 2024 – Feb 8, 2024 · Past
Michelle Yanez
Other companies: Inhibitor Therapeutics Inc. (Director · Since at least Dec 13, 2022); MIRA Pharmaceuticals, Inc. (Chief Financial Officer · Aug 2, 2023 – Dec 9, 2024 · Past)
Chief Financial Officer · Jun 18, 2024 – Aug 27, 2024 · Past
Andriy Mushak
Other companies: MIRA Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jun 2, 2026)
Chief Financial Officer · Since at least Jun 3, 2026
Bradley Kroenig
Other companies: MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 2, 2023 · Past)
Director · Feb 8, 2024 – Feb 8, 2024 · Past
Christos Nicholoudis
Other companies: MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 17, 2023 · Past)
General Counsel, Director · Feb 8, 2024 – Feb 8, 2024 · Past
Edward Clouston MacPherson
Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Mar 13, 2024)
Director · Since at least Aug 8, 2024
All 16 people
PersonSeat
Erez Aminov
Other companies: MIRA Pharmaceuticals, Inc. (Chairman of the Board and Chief Executive Officer · Since at least Aug 2, 2023)
Chairman and Chief Executive Officer · Since at least Aug 8, 2024
Matthew Del Giudice
Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Mar 13, 2024)
Director · Since at least Aug 8, 2024
Matthew Pratt Whalen
Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024)
Director · Since at least Aug 8, 2024
Nathen Fuentes
Other companies: Lunai Bioworks Inc. (Chief Financial Officer · Jan 6, 2025 – Jan 21, 2025 · Past)
Chief Financial Officer · Feb 8, 2024 – Feb 8, 2024 · Past
Ned MacPherson
Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Nov 4, 2026)
Director · Since at least Nov 4, 2026
Talhia Tuck
Other companies: MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 2, 2023 · Past)
Director · Feb 8, 2024 – Feb 8, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Telomir Pharmaceuticals, Inc.